Our rationale for conducting this study was to determine if posiphen and phenserine are two 5′UTR-directed drugs that would reduce alpha-synuclein expression to provide therapeutic benefit to Parkinson's disease patients. The gene discussed is SNCA; the disease is Parkinson disease.